PDCD1 and melanoma: Including the analysis of TCR-CDR3 sequence in clinical trials like this could be the standard technique for immunomonitoring the repertoire of T cells and their response to cell transfer as a vaccine or as evaluated by others using neoantigens and anti-PD-1 treatment in melanoma patients (48).